This funding opportunity supports exploratory and developmental phased clinical trial research (R61/R33) focused on treating critical and co-occurring health conditions in individuals with Down syndrome. It funds up to two years of preliminary studies followed by up to three years of clinical trial support, requiring measurable milestones and a total project period not exceeding five years.
Eligible applicants include a wide range of U.S.-based organizations such as county and state governments, nonprofits, for-profit organizations, small businesses, educational institutions, tribal organizations, and public housing authorities. Specific eligibility details are provided in the funding
